Table 5 PROs prior, during and at the end of treatment among dual and triple users

Baseline

 BMI-T0

31.26 ± 4.16

29.92 ± 4.26

.31

 HRQoL-T0

32.54 ± 21.23

30.74 ± 17.67

.85

 Symptom Severity-T0

23.32 ± 13.14

22.93 ± 11.24

.97

 Symptom Hindrance-T0

9.22 ± 9.09

7.80 ± 7.50

.64

 MSPSS-T0

2.22 ± .57

2.49 ± .39

.05

 Depression-T0

9.12 ± 7.51

8.09 ± 6.92

.59

 Anxiety-T0

6.41 ± 5.83

7.51 ± 6.03

.53

 Stress-T0

8.64 ± 6.61

10.80 ± 7.63

.29

After 5/6 weeks

 BM-IT1

31.24 ± 4.47

29.60 ± 4.50

.16

 HRQoL-T1

31.06 ± 24.06

41.54 ± 21.62

.04

 Symptom Severity-T1

21.77 ± 15.09

28.51 ± 12.72

.05

 Symptom Hindrance-T1

9.29 ± 9.64

13.03 ± 9.67

.09

 MSPSS-T1

2.34 ± .55

2.54 ± .38

.23

 Depression-T1

9.12 ± 7.67

9.48 ± 7.15

.72

 Anxiety-T1

5.64 ± 5.77

9.19 ± 6.16

.01

 Stress-T1

9.00 ± 7.46

11.87 ± 7.09

.11

 INDEXSCORE-T1

15.74 ± .77

15.45 ± 1.45

.87

At the end of therapy

 HRQoL-T2

26.60 ± 17.01

37.53 ± 20.47

.15

 Symptom Severity-T2

18.20 ± 12.50

26.57 ± 12.29

.06

 Symptom Hindrance-T2

8.40 ± 5.10

10.96 ± 8.72

.52

 MSPSS-T2

2.40 ± .40

2.41 ± .40

.84

 Depression-T2

6.20 ± 6.49

10.03 ± 6.40

.10

 Anxiety-T2

4.50 ± 3.53

7.76 ± 6.61

.27

 Stress-T2

6.40 ± 5.16

11.03 ± 6.99

.08

 INDEXSCORE-T2

15.90 ± .31

15.30 ± 1.46

.41